JNJ-77242113 for Plaque Psoriasis
(ICONIC-LEAD Trial)
Trial Summary
What is the purpose of this trial?
This trial is testing a new medication called JNJ-77242113 to see if it helps people with moderate to severe plaque psoriasis. Plaque psoriasis is a skin condition that causes red, scaly patches. The study aims to find out if this new treatment can improve symptoms for those who have not responded well to other treatments.
Do I need to stop my current medications to join the trial?
The trial information does not specify if you need to stop taking your current medications. However, if your psoriasis is drug-induced, you may not be eligible to participate.
Is JNJ-77242113 safe for treating plaque psoriasis?
Research on similar treatments, called JAK inhibitors, shows they generally have a safety profile similar to a placebo (a harmless pill used in studies for comparison). However, some specific JAK inhibitors like deucravacitinib at certain doses had more side effects, while others like tofacitinib were found to be safer.12345
Research Team
Janssen Research & Development, LLC Clinical Trial
Principal Investigator
Janssen Research & Development, LLC
Eligibility Criteria
This trial is for adolescents and adults with moderate to severe plaque psoriasis, who have had the condition for at least 6 months. They should need phototherapy or systemic treatment and have a significant area of their body affected. Women able to bear children must test negative for pregnancy.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Initial Treatment
Participants receive JNJ-77242113 or placebo from Week 0 to Week 16
Re-randomization and Continued Treatment
Adult participants who respond are re-randomized to continue JNJ-77242113 or switch to placebo, with retreatment upon loss of response. Adolescents continue JNJ-77242113.
Long-term Treatment
All participants receive JNJ-77242113 from Week 52 to Week 156
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- JNJ-77242113
Find a Clinic Near You
Who Is Running the Clinical Trial?
Janssen Research & Development, LLC
Lead Sponsor
Giacomo Salvadore
Janssen Research & Development, LLC
Chief Medical Officer since 2023
MD from the University of Rome, Tor Vergata
Ricardo Attar
Janssen Research & Development, LLC
Chief Executive Officer since 2008
PhD in Molecular Biology from the University of Buenos Aires